Brainstorm Cell Therapeutics Net Income

Brainstorm Cell Therapeutics (BCLI) currently reports a net income of $14M as of June 2026. That compares with $-11M in the prior-year period — up 225.3% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Brainstorm Cell Therapeutics's net income history and peer comparisons.

Brainstorm Cell Therapeutics's net income increased from $-11M to $14M — a 225.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brainstorm Cell Therapeutics's net income of $14M is lower than the Healthcare sector average of $17B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Brainstorm Cell Therapeutics reported $14M in net income as of June 2026. That compares with $-11M in the prior-year period — up 225.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Brainstorm Cell Therapeutics, and consider following BCLI for alerts when major investors trade the stock.